SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Rantapää Dahlqvist Solveig)
 

Search: WFRF:(Rantapää Dahlqvist Solveig) > (2015-2019) > Co-morbidity in pat...

Co-morbidity in patients with early rheumatoid arthritis - inflammation matters

Innala, Lena, 1060- (author)
Umeå universitet,Reumatologi
Sjöberg, Clara, 1986- (author)
Umeå universitet,Reumatologi
Möller, Bozena (author)
show more...
Ljung, Lotta, 1964- (author)
Umeå universitet,Reumatologi
Smedby, Torgny (author)
Södergren, Anna, 1977- (author)
Umeå universitet,Reumatologi
Magnusson, Staffan (author)
Rantapää-Dahlqvist, Solbritt, 1947- (author)
Umeå universitet,Reumatologi
Wållberg-Jonsson, Solveig, 1953- (author)
Umeå universitet,Reumatologi
show less...
 (creator_code:org_t)
2016-01-28
2016
English.
In: Arthritis Research & Therapy. - : BioMed Central. - 1478-6362. ; 18
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background: Patients with rheumatoid arthritis (RA) suffer from co-morbidities that contribute to a shortened lifespan. Inflammation is important for the development of cardiovascular disease, but little is known on its relationship with other co-morbidities. We investigated the role of inflammation for the development of new comorbidities in early RA. Methods: Since 1995, all patients with early RA in Northern Sweden are included in a prospective study on comorbidities, with a total of 950 patients being included. At the time for this study, 726 had been ill for >= 5 years. Data on co-morbidities, clinical and laboratory disease activity and pharmacological therapy were collected from patient records and further validated using a questionnaire at RA onset (T0) and after 5 years (T5). Results: Of the patients, 53.2 % of the patients had one or more co-morbidity at onset, the commonest being: hypertension (27.3 %), obstructive pulmonary disease (13.9 %), diabetes (8.0 %), hypothyroidism (6.3 %) and malignancy (5.0 %). After 5 years, 41.0 % had developed at least one new co-morbidity, the most common being: hypertension (15.1 %), malignancy (7.6 %), stroke/transient ischemic accident (5.1 %), myocardial infarction (4.3 %) and osteoporosis (3.7 %). Age at disease onset, a raised erythrocyte sedimentation rate (ESR) at inclusion, previous treatment with glucocorticoids (GC; p < 0.001 for all), extra-articular RA (Ex-RA; p < 0.01), DAS28 (area under the curve) at 24 months (p < 0.05), previous smoking at inclusion (p = 0.058) and male gender (p < 0.01) were associated with a new co-morbidity overall at T5. Treatment with biologics (p < 0.05) reduced the risk. In multiple logistic regression modelling, ESR (p = 0.036) at inclusion was associated with a new co-morbidity after 5 years, adjusted for age, sex, smoking and GC treatment. In a similar model, Ex-RA (p < 0.05) was associated with a new co-morbidity at T5. In a third model, adjusted for age and sex, a new pulmonary co-morbidity was associated with a smoking history at inclusion (p < 0.01), but not with ESR. Conclusion: There was substantial co-morbidity among early RA patients already at disease onset, with considerable new co-morbidity being added during the first five years. Measures of disease activity were associated with the occurrence of a new co-morbidity indicating that the inflammation is of importance in this context.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)

Keyword

Early rheumatoid arthritis
Co-morbidity
Inflammation

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view